Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.78 | $346.80 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,298 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 09, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.78 | $346.80 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 13 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,767,222 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 08, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $5.79 | $289.50 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 21 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,054 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 08, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.81 | $377.65 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,937 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 08, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.81 | $348.60 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,238 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 08, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.81 | $348.60 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 12 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,767,162 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 07, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.74 | $373.10 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,872 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 07, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.74 | $344.40 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,178 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 07, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.74 | $344.40 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 11 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,767,102 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 04, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $5.75 | $287.50 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 20 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,004 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 04, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.76 | $374.40 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,807 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 04, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.76 | $345.60 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,118 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 04, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.76 | $345.60 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 10 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,767,042 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 02, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.77 | $375.05 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,742 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 02, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.77 | $346.20 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 02, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.77 | $346.20 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 9 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,982 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 01, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $5.83 | $291.50 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 19 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,954 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 01, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.89 | $382.85 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,677 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 01, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.89 | $353.40 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,998 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| October 01, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.89 | $353.40 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 8 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,922 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 30, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.89 | $382.85 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 7 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,612 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 30, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.89 | $353.40 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 7 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,938 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 30, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.89 | $353.40 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 7 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,862 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 27, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.76 | $374.40 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 6 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,547 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 27, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.76 | $345.60 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 6 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,878 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 27, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.76 | $345.60 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 6 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,802 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 26, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.81 | $435.75 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 18 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,904 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 26, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.76 | $374.40 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 5 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,482 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 26, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.76 | $345.60 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 5 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,818 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 26, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.76 | $345.60 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 5 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,742 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 3,470 | $5.31 | $18,425.70 |
DisclosureSEC source: 0001209191-19-051031 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.20, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.20, inclusive. Read SEC document |
| September 25, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.38 | $349.70 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 4 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,417 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 25, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.38 | $322.80 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 4 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,758 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 25, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.38 | $322.80 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 4 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,682 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 24, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.39 | $350.35 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 3 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,352 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 24, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.39 | $323.40 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 3 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,698 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 24, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.39 | $323.40 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 3 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,622 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 23, 2019 Filed Sep 27, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 4,400 | $5.27 | $23,188.00 |
DisclosureSEC source: 0001209191-19-051031 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,470 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.20, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.31 to $5.21, inclusive. Read SEC document |
| September 23, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.37 | $402.75 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 17 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,829 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 23, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.35 | $347.75 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,287 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 23, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.35 | $321.00 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,638 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 23, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.35 | $321.00 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 2 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,562 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 20, 2019 Filed Sep 27, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 3,700 | $5.31 | $19,647.00 |
DisclosureSEC source: 0001209191-19-051031 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,870 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.20, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.25, inclusive. Read SEC document |
| September 20, 2019 Filed Oct 25, 2019 21:14 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.33 | $346.45 |
DisclosureSEC source: 0001209191-19-054167 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,422 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 20, 2019 Filed Oct 25, 2019 21:12 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.33 | $319.80 |
DisclosureSEC source: 0001209191-19-054164 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,578 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 20, 2019 Filed Oct 25, 2019 21:13 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.33 | $319.80 |
DisclosureSEC source: 0001209191-19-054166 · doc4.xml · nonDerivative · entry 1 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,502 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.21 | $312.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 30 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,518 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 4,000 | $5.21 | $20,840.00 |
DisclosureSEC source: 0001209191-19-050361 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,170 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.13, inclusive. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.21 | $338.65 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 30 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,157 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.21 | $312.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 30 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766,442 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.